Linifanib (ABT-869)

Linifanib (ABT-869)は一種の新たで、有効なATP競争性的なVEGFR/PDGFR阻害剤で、KDR、CSF-1R、Flt-1/3とPDGFRβに作用する時のIC50値が4 nM、3 nM、3 nM/4 nMと66 nMにそれぞれ別れることですが、突然変容キナーゼ依頼性細胞(FLT3)に作用する効果が一番強いです。臨床3期。

価格 在庫  
USD 151 あり
USD 226 あり
USD 264 あり
USD 718 あり

Linifanib (ABT-869) 化学構造
分子量: 375.41





  • Compare VEGFR Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 Linifanib (ABT-869)は一種の新たで、有効なATP競争性的なVEGFR/PDGFR阻害剤で、KDR、CSF-1R、Flt-1/3とPDGFRβに作用する時のIC50値が4 nM、3 nM、3 nM/4 nMと66 nMにそれぞれ別れることですが、突然変容キナーゼ依頼性細胞(FLT3)に作用する効果が一番強いです。臨床3期。
ターゲット KDR CSF-1R Flt-1 Flt-3 PDGFRβ
IC50 4 nM 3 nM 3 nM 4 nM 66 nM [1]
In vitro試験 Linifanib shows inhibitory to Kit, PDGFRβ and Flt4 with IC50 of 14 nM, 66 nM and 190 nM in kinases assay. Linifanib also inhibits ligand-induced KDR, PDGFRβ, Kit, and CSF-1R phosphorylation with IC50 of 2 nM, 2 nM, 31 nM and 10 nM at cellular level and this cellular potency could be affected by serum protein. Linifanib suppresses VEGF-stimulated HUAEC proliferation with IC50 of 0.2 nM. While Linifanib has weak activity against tumor cells which are not induced by VEGF or PDGF, except for MV4-11 leukemia cells (with constitutively active form of Flt3) with IC50 of 4 nM. Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells. [1] Linifanib binds to the ATP-binding site of CSF-1R with Ki of 3 nM. [2] Linifanib (10 nM) exhibits a reduced phosphorylation of Akt at Ser473 and decreased phosphorylation of GSK3βat Ser9 in Ba/F3 FLT3 ITD cell lines. [3]
In vivo試験 Linifanib (0.3 mg/kg) results in complete inhibition of KDR phosphorylation in lung tissue. Linifanib also inhibits the edema response with ED50 of 0.5 mg/kg. Linifanib (7.5 and 15 mg/kg, bid) significantly inhibits both bFGF- and VEGF-induced angiogenesis in the cornea. Linifanib inhibits tumor growth in flank xenograft models including HT1080, H526, MX-1 and DLD-1 with ED75 from 4.5-12 mg/kg. Linifanib also shows efficacy in A431 and MV4-11 xenografts at low dose levels. Linifanib (12.5 mg/kg bid) reveals a decrease of microvasculure density in MDA-231 xenograft. Linifanib shows a Cmax and AUC24 hours with 0.4 μg/mL and 2.7 μg•hour/mL in HT1080 fibrosarcoma model. [1]
臨床試験 Linifanib is in a Phase III evaluation for hepatocellular carcinoma.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Kinase assays Potencies (IC50 values) are determined by assays of active kinase domains cloned and expressed in baculovirus using the FastBacbaculovirus expression system or obtained commercially. For tyrosine kinase assays, a biotinylated peptide substrate containing a single tyrosine is used with 1 mM ATP, anEu-cryptate–labeled anti-phosphotyrosine antibody (PT66), and Strepavidin-APC in a homogeneous time-resolved fluorescence assay. Serine/threonine kinases are assayed using 5 μM ATP, [33P]ATP, and a biotinylated peptide substrate with peptide capture and incorporation of 33P determined using a SA-Flashplate. Linifanib is assayed at multiple concentrations prepared by serial dilution of a DMSO stock solution of Linifanib. The concentration resulting in 50% inhibition of activity is calculated using nonlinear regression analysis of the concentration response data.

細胞アッセイ: [1]

細胞株 HUAEC, HT-29, HT1080, A431, MDA-435, MDA-231, H526, DLD-1, 9L and MV4-11 cells
濃度 0-100 μM
反応時間 72 hours
実験の流れ Cells are seeded into 96-well plates at 2.5 × 103 per well and incubated with serum-free medium for 24 hours. Linifanib and VEGF (final, 10 ng/mL) are added and incubated for 72 hours in serum-free medium. For carcinoma cell lines, 3 × 103 cells/well are plated overnight in full growth medium. Linifanib is added to the cells in full growth medium and incubated for 72 hours. For leukemia cells, generally 5 × 104 per well are plated in full growth medium, Linifanib is added, and incubated for 72 hours. The effects on proliferation are determined by addition of Alamar Blue (final solution, 10%), incubation for 4 hours at 37 °C in a CO2 incubator and analysis in a fluorescence plate reader (544 nm, excitation: 590 nm, emission

動物実験: [1]

動物モデル H526, DLD-1, MDA-231, MDA-435LM, HCT-116, H526, DLD-1, MDA-231, MDA-435LM, MV4-11 and MX-1 xenografts are established in mice.
製剤 2% ethanol, 5% Tween 80, 20% PEG400, 73% saline
投薬量 ~ 10 mg/kg
投与方法 Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Linifanib (ABT-869) SDF
分子量 375.41


CAS No. 796967-16-3
保管 3年-20℃
2年-80℃in solvent
別名 AL39324,RG3635
溶解度 (25°C) * In vitro DMSO 75 mg/mL (199.78 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea

文献中の引用 (5)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related VEGFR 阻害剤

  • SU5402

    SU5402は一種の有効で、多ターゲット受容体キナーゼ阻害剤で、VEGFR2、FGFR1とPDGF-Rβに作用する時のIC50値が20 nM、30 nMと510 nMにそれぞれ分かれます。

  • Erlotinib

    Erlotinibは一種のEGFR阻害剤で、このIC50値が2 nMです。Erlotinibは、EGFRに対する敏感性は人間c-Src或いはv-Abに対する敏感性より1000倍以上が高くなります。

  • R428 (BGB324)

    R428 (BGB324)は一種のAxl阻害剤で、IC50値が14 nMです。R428 (BGB324)は、Axlに作用する選択性はAblに作用する選択性より100倍以上が高くなって、MerとTyro3に作用する選択性より50倍-100倍が高くなって、InsR、EGFR、HER2とPDGFRβに作用する選択性より100倍余りが高くなります。

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397)は一種の経口有効な多ターゲットCSF-1R、KitとFlt3受容体チロシンキナーゼ阻害剤で、IC50値が20 nM、10 nMと160 nMにそれぞれ分かれることです。臨床3期。

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR1、VEGFR2、VEGFR3、PDGFR-β、Kit、RETとRaf-1に作用する時のIC50値が13 nM、4.2 nM、46 nM、22 nM、7 nM、1.5 nMと2.5 nMにそれぞれ分かれることです。

  • Axitinib

    Axitinibは一種の多ターゲット阻害剤で、ブタ大動脈内皮細胞にVEGFR1、VEGFR2、VEGFR3、PDGFRβとc-Kitに作用する時のIC50値が为0.1 nM、0.2 nM、0.1-0.3 nM、1.6 nMと1.7 nMにそれぞれ分かれることです。

    Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351)は一種の有効なVEGFR2阻害剤で、無細胞試験でIC50値が0.035 nMです。Cabozantinib (XL184, BMS-907351)はc-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXLに有効に作用する時のIC50値が1.3 nM,4 nM,4.6 nM,12 nM/11.3 nM/6 nM,14.3 nM 和 7 nMにそれぞれ分かれます。

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120)は一種の有効な三重血管キナーゼ阻害剤で、無細胞試験でVEGFR1/2/3、FGFR1/2/3とPDGFRα/βに作用する時のIC50値が34 nM/13 nM/13 nM、69 nM/37 nM/108 nMと59 nM/65 nMにそれぞれ分かれることです。臨床3期。

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474)は一種の有効なVEGFR2阻害剤で、無細胞試験でIC50値が40 nMです。

  • Lenvatinib (E7080)

    Lenvatinib (E7080)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR2(KDR)/VEGFR3(Flt-4)に作用する効果が一番強くて、IC50値が4 nM/5.2 nM,になることです。Lenvatinib (E7080)はVEGFR1/Flt-1に作用する効果が少し弱くて、VEGFR2/3に作用する選択性はFGFR1とPDGFRα/βに作用する選択性より10倍左右がそれぞれ高くなります。臨床3期。


Tags: Linifanib (ABT-869)を買う | Linifanib (ABT-869)供給者 | Linifanib (ABT-869)を購入する | Linifanib (ABT-869)費用 | Linifanib (ABT-869)生産者 | オーダーLinifanib (ABT-869) | Linifanib (ABT-869)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID